WHO calls for closer monitoring of commercial interests

BMJ 2002; 324 doi: (Published 05 January 2002) Cite this as: BMJ 2002;324:8
  1. Rohit Sharma
  1. Mumbai

    Commercial interests are posing such an increasing threat to the integrity of clinical trials necessary for developing new drugs that new regulations are needed to safeguard them from corruption, according to Dr Jonathan Quick, director of essential drugs and medical policy at the World Health Organization.

    In an editorial in the current Bulletin of …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription